Ocumetics Technology

Ocumetics Technology FCF Yield

The Free Cash Flow Yield of Ocumetics Technology (OTC.V) as of Nov 20, 2026 is -15.32 %. In the previous year, Free Cash Flow Yield was -11.03 % — a change of 38.84% (lower).

FCF Yield

-15.32 %

YoY

38.84%

Last updated:

Free Cash Flow Yield of Ocumetics Technology is 2025 -15.32 % . Free Cash Flow Yield of Ocumetics Technology was 2024 -11.03 % . It decreases by 38.84% lower compared to the previous year.

The Ocumetics Technology FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-0.21 CAD
Jan 1, 2019
0.00 CAD
Jan 1, 2020
-0.00 CAD
Jan 1, 2021
-0.94 CAD
Jan 1, 2022
-7.39 CAD
Jan 1, 2023
-9.60 CAD
Jan 1, 2024
-11.03 CAD
Jan 1, 2025
-15.32 CAD
The Ocumetics Technology FCF Yield history
YEARFCF YieldYoY
-15.32 %+38.84%
-11.03 %+14.91%
-9.60 %+29.85%
-7.39 %+688.93%
-0.94 %+26,047.86%
-0.00-180.97%
0.00-102.11%
-0.21 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ocumetics Technology Stock analysis

What does Ocumetics Technology do? Ocumetics Technology Corp develops the Bionic Lens, an expandable intraocular lens designed for people over 45 to eliminate corrective lenses. The company focuses on adaptive lens designs for intraocular lenses that allow natural eye muscle activity to shift focus between distance and near vision. The Bionic Lens uses self-adapting suspension systems with cushions conforming to each recipient’s eye parameters, compressing the optical interface during relaxation of ciliary muscles for distant focus. The firm is in preclinical study stage for ophthalmic industry technology. Ocumetics Technology Corp specializes in intraocular lens development targeting the ophthalmic industry segment. The Bionic Lens is the company’s primary product, designed to fit within the natural lens compartment of the eye without requiring corrective lenses. The company’s technology aims to address the needs of individuals over 45 years of age who seek alternatives to traditional corrective lenses. The preclinical study stage indicates the company is developing its product for future market entry in the ophthalmic sector. The Bionic Lens features a unique suspension system that modulates curvature change through self-adapting cushions. These cushions conform to individual eye parameters, enabling the lens to shift focus naturally with ciliary muscle activity. The product’s design eliminates the need for corrective lenses by leveraging the eye’s natural mechanisms for focusing on distant objects during muscle relaxation. Ocumetics Technology Corp is positioned to serve the aging population seeking vision correction solutions without traditional eyewear. Ocumetics Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ocumetics Technology stock

Free Cash Flow Yield of Ocumetics Technology is -15.32 % in 2025.

Free Cash Flow Yield of Ocumetics Technology changed from -11.03 % to -15.32 %, representing a 38.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Ocumetics Technology since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Ocumetics Technology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Ocumetics Technology

All Key Metrics — Ocumetics Technology